Global Blood Therapeutics (GBT), a biopharmaceutical company dedicated to the discovery, development and delivery of life-changing treatments that provide hope to underserved patient communities, starting with sickle cell disease, appointed Reza Afkhami as Senior Vice President of Corporate Development and Strategy. Reza brings more than 17 years of global business development, corporate strategy, commercial planning…
Category: BIOPHARMACEUTICALS
Chartwell Partners was honored to work with HemoShear Therapeutics on the recruitment of Pat Horn as Chief Medical Officer. Based in Charlotteville, VA, HemoShear is a privately held clinical stage company developing treatments for rare metabolic disorders with significant unmet patient need. HST5040, an oral small molecule drug, is HemoShear’s lead development program and is…
Chartwell Partners recruited industry executive and neurologist, Chris Kenney, MD, as Chief Medical Officer for Xenon Pharmaceuticals, a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. Most recently, Dr. Kenney served as Chief Medical Officer for Cadent Therapeutics, a company focused on developing positive allosteric…
Chartwell Partners is honored to have been selected to partner with Allakos on the recruitment of Baird Radford as Chief Financial Officer. Mr. Radford’s experience helping to lead companies through the transition from R&D to commercial stage will be a distinct advantage as Allakos prepares for potential commercialization of its first product candidate. Most recently,…
We are delighted to announce the recruitment of Ian Hunt as SVP, Regulatory Affairs for Akebia Therapeutics, a public, Cambridge, MA-based biopharmaceutical company committed to bettering the lives of people impacted by kidney disease. Most recently, Ian served as Vice President and Head of Regulatory Affairs for GSK’s Infectious Disease, Neuroscience and CV/Renal franchises, a…
Chartwell is delighted to have served as executive search partner to Prothena for the Company’s recruitment of its Chief Medical Officer, Hideki Garren, MD, PhD. The breadth and success of Dr. Garren’s neuroscience drug development experience will be distinct advantages as Prothena looks towards the continued development, registration, and commercialization of its first assets. Most…
Molly Ryan has joined GBT to lead the Company’s global initiatives in government affairs and policy. As GBT continues its focus on the discovery, development and delivery of life-changing treatments for underserved patient communities, beginning with sickle cell disease, Ms. Ryan will leverage her extensive biotechnology and pharmaceutical experience as a trusted and recognized expert…
Chartwell Partners is pleased to announce the recruitment of Petra Kaufmann, MD, as Chief Medical Officer for Affinia Therapeutics, a next generation gene therapy company utilizing its proprietary platform to engineer novel vectors and gene therapies for rare and non-rare diseases. Dr. Kaufmann brings to Affinia substantial expertise in neuroscience translational medicine and clinical development…
Chartwell Partners is pleased to announce the appointment of Salisa Hauptmann, MPH, as Senior Vice President, Regulatory Affairs for BioCryst Pharmaceuticals, a company pioneering the discovery, development and commercialization of oral, small molecule medicines to treat rare diseases. Salisa brings more than 25 years of global regulatory expertise to BioCryst, including significant work with rare,…
Chartwell Partners is pleased to announce the recruitment of Esin Kosal, PhD as SVP, Regulatory Affairs for EryDel SpA, a global biotechnology company utilizing its proprietary red blood cell drug delivery technology to encapsulate small and large molecules into a patient’s own red blood cells which are then reinfused into that patient in a fast,…